Definium Therapeutics Inc to Review Phase 3 Voyage Topline Results Transcript
Hello and welcome to the Definium Therapeutics Phase 3 Voyage Top-Line Results Call. We ask that you please hold all questions until the end of the prepared remarks, at which time you'll be given instructions for the question-and-answer session.
As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time.
I would now like to pass the call over to Rob Barrow, Chief Executive Officer. Please proceed.
Thank you, operator. Hello, everyone, and thank you for joining us this morning. I'm Rob Barrow, Chief Executive Officer of Defendium Therapeutics, and I'm joined today by our Chief Medical Officer, Dr. Dan Carlin, and our Chief Financial Officer, Brandy Roberts.
We could not be more excited to be here with you this morning to share the unprecedented top-line results from Voyage, our first pivotal study of DT120 ODT and generalized anxiety disorder, or GAD.
Before we get started, please note that on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
